Join our daily newsletter At The Bell to receive exclusive market insights
- Bod Australia (BDA) will launch a new medicinal cannabis product under its existing MediCabilis brand to the Australian market in July
- The product will be sold as Bod Bio-Absorb 100 and is made up of a uniquely developed CBD formulation in a soft gel format
- The launch of Bio-Absorb 100 will expand Bod’s medicinal cannabis range, complement its existing products and introduce a new delivery format
- To drive product awareness, Bod has engaged multiple healthcare professionals and prescribers to further educate them on the benefits of Bio-Absorb 100
- Bod ends the day 12.7 per cent in the green with shares trading at eight cents
Bod Australia (BDA) will launch a new medicinal cannabis product under its existing MediCabilis brand to the Australian market in July.
The product will be sold as Bod Bio-Absorb 100 and is made up of a uniquely developed CBD formulation in a soft gel format.
It is currently undergoing a phase II clinical trial and, once completed, it will be sold over-the-counter through pharmacies.
The launch of Bio-Absorb 100 will expand Bod’s medicinal cannabis range, complement its existing products and introduce a new delivery format.
To drive product awareness, Bod has engaged multiple healthcare professionals and prescribers to further educate them on the benefits of Bio-Absorb 100.
Further, it is available to consumers through the Therapeutic Goods Administration’s (TGA) Special Access Scheme Category B (SAS-B).
The TGA’s SAS allows healthcare practitioners to access therapeutic goods such as medicines, medical devices and biologicals that are not included in the Australian Register of Therapeutic Goods.
“The launch of Bod Bio-Absorb 100 provides Bod with another product in the Australian
medicinal cannabis prescription market, which has the potential to increase sales and brand awareness,” CEO Jo Patterson said.
“Importantly, the introduction of the product through prescription channels will also provide us with valuable feedback as we continue our clinical trial and endeavour to launch Bod Bio-Absorb 100 through the Australian pharmacy market in the coming months.”
Bod has ended the day 12.7 per cent in the green with shares trading at 8 cents.
